The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before the cancer comes back. Researchers at UCLA have found that a blend of a ...

Willy Goldschmidt is among a group of patients from University Hospitals Coventry and Warwickshire NHS Trust who have taken ...

A former prostate cancer patient who got the all-clear said taking part in a trial that cut his radiotherapy treatments ...

Phase III trial presented at ASTRO in San Francisco finds five-treatment regimen poised to become new standard of care. The principal investigator of the trial, Ellis is a radiation oncologist and ...

Anyone discouraged by the continued absence of a prostate cancer screening programme, the difficulties in getting a clear ...

Stereotactic body radiotherapy (SBRT) alone achieves a 69.7% pooled 1- or 2-year systemic therapy-free survival rate across cancer types, with the highest rates seen in renal cell and prostate cancers ...

MiraDx Announces the Commercial Availability of PROSTOX™ ultra for Prediction of Risk of Late Genitourinary Toxicity in Prostate Cancer Patients Considering Radiation Therapy MiraDx, a molecular ...